查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1586396

澱粉樣變性治療市場、規模、佔有率、趨勢、行業分析報告：按治療、按最終用戶、按地區 - 市場預測，2024-2032

Amyloidosis Treatment Market Size, Share, Trends, Industry Analysis Report: By Treatment, End User, and Region - Market Forecast, 2024-2032
出版日期: | 出版商: Polaris Market Research | 英文 117 Pages | 商品交期: 最快1-2個工作天內

價格

根據 Polaris Market Research 的最新研究，到 2032 年，全球澱粉樣變性治療市場預計將達到 97.9 億美元。該研究報告提供了對當前市場動態的詳細洞察，並對未來市場成長進行了分析。

澱粉樣變性治療市場是更廣泛的醫療保健領域的重要組成部分。澱粉樣變性治療市場專注於治療一組罕見但嚴重的疾病，其特徵是澱粉樣蛋白在各種組織和器官中異常沉積。澱粉樣變性分為多種類型，包括 AL（輕鏈）、AA（繼發性）、遺傳性和野生型 ATTR（運甲狀腺素蛋白澱粉樣變性）。這些病症的複雜性需要多種治療方案，從而帶來顯著的市場進步。

由於對疾病機制的深入瞭解和診斷技術的改進，澱粉樣變性治療市場在過去幾十年中不斷發展。從歷史上看，澱粉樣變性的治療選擇有限，通常與患者預後不良相關。然而，隨著達雷妥尤單抗和他法米迪等新療法的推出，澱粉樣變性的治療發生了顯著變化。

由於認識提高、持續研究和開發以及人口老化加劇等多種因素，全球澱粉樣變性治療市場正在擴大。此外，影像和生物標記識別等診斷技術的進步正在促進早期診斷，這對於有效治療澱粉樣變性至關重要。

澱粉樣變性治療市場報告重點

在澱粉樣變性治療市場中，根據最終用途，由於對以患者為中心的治療的偏好不斷增加，預計家庭護理領域在預測期內將出現顯著增長。

醫院和診所憑藉其完善的基礎設施以及能夠處理複雜澱粉樣變性病例的專業醫務人員，在 2023 年佔據市場主導地位。

從治療方式來看，化療由於其在相關疾病（尤其是 AL 澱粉樣變性）治療方面的療效已確立，因此將在 2023 年佔據市場的主要佔有率。此外，聯合療法的進步增加了對化療的需求。

由於對 AL 澱粉樣變性患者進行造血幹細胞移植的認識不斷提高，預計移植領域在預測期內將以強勁的速度增長。

在全球市場中，由於人口老化加劇和人們對疾病的認識不斷提高，北美地區在 2023 年佔據了最大的收入佔有率。

由於慢性病的增加和醫療保健支出的增加，預計亞太市場在預測期內將出現顯著的複合年增長率。

全球主要市場參與者包括：輝瑞公司（Johnson & Johnson Services, Inc.）；武田製藥有限公司（Takeda Pharmaceutical Company Limited）；默克製藥公司（Merck KGaA）；諾華公司、Ionis 製藥公司、百時美施貴寶公司和安進公司

目錄

第1章簡介

第 2 章執行摘要

第3章研究方法

第 4 章全球澱粉樣變性治療市場洞察

  • 市場快照
  • 澱粉樣變性治療市場動態
    • 促進因素和機會
      • 診斷技術的進步正在擴大市場規模
      • 隨著世界各地臨床試驗的增加，澱粉樣變性治療市場正在不斷成長。
    • 抑制因素和課題
      • 治療成本上升預計將阻礙市場成長。
  • PESTEL 分析
  • 澱粉樣變性治療市場趨勢
  • 價值鏈分析
  • 新冠肺炎 (COVID-19) 影響分析

第5章全球澱粉樣變性治療市場：依治療分類

  • 主要發現
  • 簡介
  • 化療
  • 免疫抑制劑
  • 移植
  • 支持性護理
  • 手術
  • 其他

第 6 章全球澱粉樣變性治療市場：依最終使用者劃分

  • 主要發現
  • 簡介
  • 醫院/診所
  • 門診手術中心
  • 居家照護環境
  • 其他

第7章全球澱粉樣變性治療市場：按地區

  • 主要發現
  • 簡介
    • 澱粉樣變性治療市場評估：地區，2019-2032
  • 北美
    • 北美：治療，2019-2032 年
    • 北美：依最終使用者劃分，2019-2032 年
    • 美國
    • 加拿大
  • 歐洲
    • 歐洲：依治療方式劃分，2019-2032 年
    • 歐洲：依最終使用者劃分，2019-2032 年
    • 英國
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 荷蘭
    • 俄羅斯
    • 歐洲其他地區
  • 亞太地區
    • 亞太地區：治療，2019-2032 年
    • 亞太地區：依最終使用者劃分，2019-2032 年
    • 中國
    • 印度
    • 馬來西亞
    • 日本
    • 印尼
    • 韓國
    • 澳大利亞
    • 其他亞太地區
  • 中東/非洲
    • 中東與非洲：治療，2019-2032 年
    • 中東和非洲：按最終用戶劃分，2019-2032 年
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 南非
    • 其他中東和非洲地區
  • 拉丁美洲
    • 拉丁美洲：依處理方式劃分，2019-2032 年
    • 拉丁美洲：依最終使用者劃分，2019-2032 年
    • 墨西哥
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區

第8章競爭態勢

  • 擴張與收購分析
    • 放大
    • 收購
  • 夥伴關係/協作/協定/揭露

第9章公司簡介

  • Pfizer Inc.
  • Johnson & Johnson Services, Inc.
  • GSK plc.
  • Takeda Pharmaceutical Company Limited
  • Alnylam Pharmaceuticals, Inc.
  • Sanofi
  • Merck KGaA
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Ionis Pharmaceuticals
  • Bristol-Myers Squibb Company
  • Amgen Inc.
Product Code: PM5132

The global amyloidosis treatment market size is expected to reach USD 9.79 billion by 2032, according to a new study by Polaris Market Research. The report "Amyloidosis Treatment Market Size, Share, Trends, Industry Analysis Report: By Treatment (Chemotherapy, Immunosuppressive Drugs, Transplantation, Supportive Care, Surgery, and Others), End User, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2024-2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The amyloidosis treatment market is a critical segment of the broader healthcare landscape. It focuses on therapies for a rare but serious group of diseases characterized by the abnormal deposition of amyloid proteins in various tissues and organs. Amyloidosis is categorized into several types, including AL (light chain), AA (secondary), hereditary forms, and wild-type ATTR (transthyretin amyloidosis). The complexity of these conditions necessitates a diverse array of treatment options, which has led to significant advancements in the market.

The amyloidosis treatment market has evolved continuously over the decades, driven by a deeper understanding of the disease mechanisms and improved diagnostic techniques. Historically, there were limited treatment options for amyloidosis, often resulting in poor patient outcomes. However, the recent introduction of novel therapies such as daratumumab and tafamidis has transformed the management of this condition.

The global amyloidosis treatment market is expanding due to several factors such as rising awareness, ongoing research and development, and a rising aging population. Moreover, advancements in diagnostic technologies, including imaging and biomarker identification, are facilitating earlier diagnosis, which is crucial for the effective treatment of amyloidosis.

Amyloidosis Treatment Market Report Highlights

Based on end use, the home care settings segment in the amyloidosis treatment market is expected to experience substantial growth during the forecast period due to the rising preference for patient-centered care.

The hospitals & clinics segment dominated the market in 2023 due to their comprehensive infrastructure along with specialized medical staff equipped to handle complex cases of amyloidosis.

By treatment, the chemotherapy segment accounted for a major share of the market in 2023 due to its established efficacy in managing related conditions, particularly AL amyloidosis. Moreover, advancements in combination therapies propelled the demand for chemotherapy.

The transplantation segment is projected to grow at a robust pace during the forecast period owing to the rising recognition of hematopoietic stem cell transplantation for patients affected by AL amyloidosis.

In the global market, North America accounted for the largest revenue share in 2023 due to the rising aging population and increased awareness of the disease.

The market in Asia Pacific is estimated to register a significant CAGR during the forecast period owing to the increasing prevalence of chronic diseases coupled with growing healthcare expenditure.

A few global key market players are Pfizer Inc.; Johnson & Johnson Services, Inc.; GSK plc.; Takeda Pharmaceutical Company Limited; Alnylam Pharmaceuticals, Inc.; Sanofi; Merck KGaA; F. Hoffmann-La Roche Ltd; Novartis AG; Ionis Pharmaceuticals; Bristol-Myers Squibb Company; and Amgen Inc.

Polaris Market Research has segmented the amyloidosis treatment market report based on treatment, end user, and region:

By Treatment Outlook (Revenue, USD Billion, 2024-2032)

  • Chemotherapy
  • Immunosuppressive Drugs
  • Transplantation
  • Supportive Care
  • Surgery
  • Others

By End User Outlook (Revenue, USD Billion, 2024-2032)

  • Hospitals & Clinics
  • Ambulatory Surgical Centers
  • Home Care Settings
  • Others

By Regional Outlook (Revenue, USD Billion, 2024-2032)

  • North America
  • US
  • Canada
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Netherlands
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • Malaysia
  • South Korea
  • Indonesia
  • Australia
  • Rest of Asia Pacific
  • Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa
  • Rest of Middle East & Africa
  • Latin America
  • Mexico
  • Brazil
  • Argentina
  • Rest of Latin America

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Amyloidosis Treatment Market Insights

  • 4.1. Amyloidosis Treatment Market - Market Snapshot
  • 4.2. Amyloidosis Treatment Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Advancements in diagnostic technologies are driving the market size
      • 4.2.1.2. Increasing clinical trials worldwide are driving the amyloidosis treatment market.
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. The high cost of treatments is expected to impede market growth.
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Amyloidosis Treatment Market Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Amyloidosis Treatment Market, by Treatment

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • 5.3. Chemotherapy
    • 5.3.1. Global Amyloidosis Treatment Market, by Chemotherapy, by Region, 2019-2032 (USD billion)
  • 5.4. Immunosuppressive Drugs
    • 5.4.1. Global Amyloidosis Treatment Market, by Immunosuppressive Drugs, by Region, 2019-2032 (USD billion)
  • 5.5. Transplantation
    • 5.5.1. Global Amyloidosis Treatment Market, by Transplantation, by Region, 2019-2032 (USD billion)
  • 5.6. Supportive Care
    • 5.6.1. Global Amyloidosis Treatment Market, by Supportive Care, by Region, 2019-2032 (USD billion)
  • 5.7. Surgery
    • 5.7.1. Global Amyloidosis Treatment Market, by Surgery, by Region, 2019-2032 (USD billion)
  • 5.8. Others
    • 5.8.1. Global Amyloidosis Treatment Market, by Others, by Region, 2019-2032 (USD billion)

6. Global Amyloidosis Treatment Market, by End-use

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • 6.3. Hospitals & Clinics
    • 6.3.1. Global Amyloidosis Treatment Market, by Hospitals & Clinics, by Region, 2019-2032 (USD billion)
  • 6.4. Ambulatory Surgical Centers
    • 6.4.1. Global Amyloidosis Treatment Market, by Ambulatory Surgical Centers, by Region, 2019-2032 (USD billion)
  • 6.5. Home Care Settings
    • 6.5.1. Global Amyloidosis Treatment Market, by Home Care Settings, by Region, 2019-2032 (USD billion)
  • 6.6. Others
    • 6.6.1. Global Amyloidosis Treatment Market, by Others, by Region, 2019-2032 (USD billion)

7. Global Amyloidosis Treatment Market, by Geography

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Amyloidosis Treatment Market Assessment, By Geography, 2019-2032 (USD billion)
  • 7.3. Amyloidosis Treatment Market - North America
    • 7.3.1. North America: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
    • 7.3.2. North America: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.3.3. Amyloidosis Treatment Market - U.S.
      • 7.3.3.1. U.S.: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.3.3.2. U.S.: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.3.4. Amyloidosis Treatment Market - Canada
      • 7.3.4.1. Canada: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.3.4.2. Canada: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • 7.4. Amyloidosis Treatment Market - Europe
    • 7.4.1. Europe: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
    • 7.4.2. Europe: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.4.3. Amyloidosis Treatment Market - UK
      • 7.4.3.1. UK: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.4.3.2. UK: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.4.4. Amyloidosis Treatment Market - France
      • 7.4.4.1. France: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.4.4.2. France: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.4.5. Amyloidosis Treatment Market - Germany
      • 7.4.5.1. Germany: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.4.5.2. Germany: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.4.6. Amyloidosis Treatment Market - Italy
      • 7.4.6.1. Italy: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.4.6.2. Italy: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.4.7. Amyloidosis Treatment Market - Spain
      • 7.4.7.1. Spain: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.4.7.2. Spain: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.4.8. Amyloidosis Treatment Market - Netherlands
      • 7.4.8.1. Netherlands: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.4.8.2. Netherlands: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.4.9. Amyloidosis Treatment Market - Russia
      • 7.4.9.1. Russia: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.4.9.2. Russia: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.4.10. Amyloidosis Treatment Market - Rest of Europe
      • 7.4.10.1. Rest of Europe: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.4.10.2. Rest of Europe: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • 7.5. Amyloidosis Treatment Market - Asia Pacific
    • 7.5.1. Asia Pacific: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
    • 7.5.2. Asia Pacific: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.5.3. Amyloidosis Treatment Market - China
      • 7.5.3.1. China: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.5.3.2. China: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.5.4. Amyloidosis Treatment Market - India
      • 7.5.4.1. India: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.5.4.2. India: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.5.5. Amyloidosis Treatment Market - Malaysia
      • 7.5.5.1. Malaysia: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.5.5.2. Malaysia: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.5.6. Amyloidosis Treatment Market - Japan
      • 7.5.6.1. Japan: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.5.6.2. Japan: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.5.7. Amyloidosis Treatment Market - Indonesia
      • 7.5.7.1. Indonesia: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.5.7.2. Indonesia: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.5.8. Amyloidosis Treatment Market - South Korea
      • 7.5.8.1. South Korea: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.5.8.2. South Korea: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.5.9. Amyloidosis Treatment Market - Australia
      • 7.5.9.1. Australia: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.5.9.2. Australia: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.5.10. Amyloidosis Treatment Market - Rest of Asia Pacific
      • 7.5.10.1. Rest of Asia Pacific: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.5.10.2. Rest of Asia Pacific: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • 7.6. Amyloidosis Treatment Market - Middle East & Africa
    • 7.6.1. Middle East & Africa: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
    • 7.6.2. Middle East & Africa: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.6.3. Amyloidosis Treatment Market - Saudi Arabia
      • 7.6.3.1. Saudi Arabia: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.6.3.2. Saudi Arabia: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.6.4. Amyloidosis Treatment Market - UAE
      • 7.6.4.1. UAE: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.6.4.2. UAE: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.6.5. Amyloidosis Treatment Market - Israel
      • 7.6.5.1. Israel: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.6.5.2. Israel: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.6.6. Amyloidosis Treatment Market - South Africa
      • 7.6.6.1. South Africa: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.6.6.2. South Africa: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.6.7. Amyloidosis Treatment Market - Rest of Middle East & Africa
      • 7.6.7.1. Rest of Middle East & Africa: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.6.7.2. Rest of Middle East & Africa: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • 7.7. Amyloidosis Treatment Market - Latin America
    • 7.7.1. Latin America: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
    • 7.7.2. Latin America: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.7.3. Amyloidosis Treatment Market - Mexico
      • 7.7.3.1. Mexico: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.7.3.2. Mexico: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.7.4. Amyloidosis Treatment Market - Brazil
      • 7.7.4.1. Brazil: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.7.4.2. Brazil: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.7.5. Amyloidosis Treatment Market - Argentina
      • 7.7.5.1. Argentina: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.7.5.2. Argentina: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.7.6. Amyloidosis Treatment Market - Rest of Latin America
      • 7.7.6.1. Rest of Latin America: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.7.6.2. Rest of Latin America: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)

8. Competitive Landscape

  • 8.1. Expansion and Acquisition Analysis
    • 8.1.1. Expansion
    • 8.1.2. Acquisitions
  • 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

  • 9.1. Pfizer Inc.
    • 9.1.1. Company Overview
    • 9.1.2. Financial Performance
    • 9.1.3. Product Benchmarking
    • 9.1.4. Recent Development
  • 9.2. Johnson & Johnson Services, Inc.
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. Product Benchmarking
    • 9.2.4. Recent Development
  • 9.3. GSK plc.
    • 9.3.1. Company Overview
    • 9.3.2. Financial Performance
    • 9.3.3. Product Benchmarking
    • 9.3.4. Recent Development
  • 9.4. Takeda Pharmaceutical Company Limited
    • 9.4.1. Company Overview
    • 9.4.2. Financial Performance
    • 9.4.3. Product Benchmarking
    • 9.4.4. Recent Development
  • 9.5. Alnylam Pharmaceuticals, Inc.
    • 9.5.1. Company Overview
    • 9.5.2. Financial Performance
    • 9.5.3. Product Benchmarking
    • 9.5.4. Recent Development
  • 9.6. Sanofi
    • 9.6.1. Company Overview
    • 9.6.2. Financial Performance
    • 9.6.3. Product Benchmarking
    • 9.6.4. Recent Development
  • 9.7. Merck KGaA
    • 9.7.1. Company Overview
    • 9.7.2. Financial Performance
    • 9.7.3. Product Benchmarking
    • 9.7.4. Recent Development
  • 9.8. F. Hoffmann-La Roche Ltd
    • 9.8.1. Company Overview
    • 9.8.2. Financial Performance
    • 9.8.3. Product Benchmarking
    • 9.8.4. Recent Development
  • 9.9. Novartis AG
    • 9.9.1. Company Overview
    • 9.9.2. Financial Performance
    • 9.9.3. Product Benchmarking
    • 9.9.4. Recent Development
  • 9.10. Ionis Pharmaceuticals
    • 9.10.1. Company Overview
    • 9.10.2. Financial Performance
    • 9.10.3. Product Benchmarking
    • 9.10.4. Recent Development
  • 9.11. Bristol-Myers Squibb Company
    • 9.11.1. Company Overview
    • 9.11.2. Financial Performance
    • 9.11.3. Product Benchmarking
    • 9.11.4. Recent Development
  • 9.12. Amgen Inc.
    • 9.12.1. Company Overview
    • 9.12.2. Financial Performance
    • 9.12.3. Product Benchmarking
    • 9.12.4. Recent Development

List of Tables:

  • Table 1 Global Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 2 Global Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 3 North America: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 4 North America: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 5 U.S.: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 6 U.S.: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 7 Canada: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 8 Canada: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 9 Europe: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 10 Europe: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 11 UK: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 12 UK: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 13 France: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 14 France: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 15 Germany: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 16 Germany: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 17 Italy: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 18 Italy: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 19 Spain: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 20 Spain: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 21 Netherlands: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 22 Netherlands: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 23 Russia: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 24 Russia: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 25 Rest of Europe: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 26 Rest of Europe: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 27 Asia Pacific: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 28 Asia Pacific: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 29 China: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 30 China: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 31 India: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 32 India: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 33 Malaysia: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 34 Malaysia: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 35 Japan: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 36 Japan: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 37 Indonesia: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 38 Indonesia: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 39 South Korea: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 40 South Korea: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 41 Australia: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 42 Australia: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 43 Rest of Asia Pacific: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 44 Rest of Asia Pacific: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 45 Middle East & Africa: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 46 Middle East & Africa: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 47 Saudi Arabia: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 48 Saudi Arabia: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 49 UAE: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 50 UAE: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 51 Israel: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 52 Israel: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 53 South Africa: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 54 South Africa: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 55 Rest of Middle East & Africa: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 56 Rest of Middle East & Africa: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 57 Latin America: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 58 Latin America: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 59 Mexico: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 60 Mexico: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 61 Brazil: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 62 Brazil: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 63 Argentina: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 64 Argentina: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 65 Rest of Latin America: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 66 Rest of Latin America: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • List of Figures:
  • Figure 1. Global Amyloidosis Treatment Market, 2019-2032 (USD billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Price
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Treatment
  • Figure 7. Global Amyloidosis Treatment Market, by Treatment, 2023 & 2032 (USD billion)
  • Figure 8. Market by End-use
  • Figure 9. Global Amyloidosis Treatment Market, by End-use, 2023 & 2032 (USD billion)